FK 506 used as rescue therapy for human liver allograft recipients.

Abstract

The new Immunosuppressant, FK 506, was first used in humans on a compassionate basis, for patients suffering from intractable rejection or disabling side effects of cyclosporine (CYA) therapy.1–3 This report is a brief overview of a much larger experience with a longer follow-up, presented in detail elsewhere.4